| 标题 |
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a randomised, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 | Lancet. 2026;408(10470):1113-1124. Lenz G, Trneeny M, Burke JM, et al. |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)